Form 4: Scholar Rock CEO Executes Sell-to-Cover Transaction

CEO David Hallal sold 30,615 shares of Scholar Rock Holding Corp to satisfy tax obligations related to RSU vesting.

Summary

• David Hallal, CEO of Scholar Rock Holding Corp, sold 30,615 shares of common stock on April 16, 2026.
• The transaction was executed at an average price of $49.5745 per share.
• The sale was a mandatory 'sell-to-cover' transaction to satisfy tax withholding obligations resulting from the vesting of restricted stock units (RSUs).
• Following the transaction, the CEO maintains direct beneficial ownership of 1,639,034 shares.
• The CEO also maintains an indirect interest in 205,000 shares held by the Hallal Family Irrevocable Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative requirement for tax compliance rather than a discretionary market move.

Positives

• The transaction was non-discretionary and mandated by the company's equity incentive plan tax requirements.
• The CEO retains a significant equity stake in the company, signaling continued alignment with shareholder interests.

Negatives

• The filing reflects a reduction in the CEO's direct share count, though this is purely for tax compliance purposes.

Risks

• Future vesting of performance-based RSUs remains subject to continued service and specific performance criteria.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the reporting of an insider transaction.

Management Comments

• The sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard practice in the biotechnology sector, where executive compensation is heavily weighted toward equity to align long-term incentives with drug development milestones.

Comparison to Industry Standards

• The use of mandatory sell-to-cover transactions is consistent with standard corporate governance practices for publicly traded biotech firms like Biogen or Vertex Pharmaceuticals.
• The retention of over 1.6 million shares by the CEO is considered a strong indicator of management confidence compared to industry peers.

Related Party Transactions

• The reporting person's spouse serves as a trustee of the Hallal Family Irrevocable Trust, which holds 205,000 shares.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and tax-related.

Next Steps

• Continued vesting of remaining time-based and performance-based RSUs subject to service requirements.

Key Dates

Keywords

Scholar Rock, SRRK, Insider Trading, Form 4, Sell-to-Cover, Executive Compensation